	US 11,896,629 B2
	Probiotic therapies for treating Rett syndrome
Sarkis K Mazmanian, Porter Ranch, CA (US); Paul H Patterson, Altadena, CA (US); Janet Chow, Alhambra, CA (US); Elaine Hsiao, Rowland Heights, CA (US); and Sara W McBride, Pasadena, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Jul. 22, 2020, as Appl. No. 16/935,837.
Application 15/249,870 is a division of application No. 13/267,748, filed on Oct. 6, 2011, granted, now 9,452,189, issued on Sep. 27, 2016.
Application 16/935,837 is a continuation of application No. 15/249,870, filed on Aug. 29, 2016, abandoned.
Claims priority of provisional application 61/472,963, filed on Apr. 7, 2011.
Claims priority of provisional application 61/391,004, filed on Oct. 7, 2010.
Prior Publication US 2021/0000888 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 35/00 (2006.01)

CPC A61K 35/741 (2013.01) [A61K 2035/11 (2013.01)]

11 Claims

1. A method for ameliorating Rett syndrome or a symptom thereof in a subject in need thereof, consisting of administering to the subject a single composition comprising a single Bacteroides bacteria species, wherein the bacterial species is B fragilis, B. thetaiotaomicron, or B. vulgatus.